In This Article:
The Australian market has shown a mixed performance, with the ASX200 closing slightly up at 7,942 points, driven by gains in the IT and Health Care sectors. In this fluctuating environment, identifying growth companies with high insider ownership can be particularly appealing to investors seeking alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Alfabs Australia (ASX:AAL) | 10.8% | 40.9% |
| Fenix Resources (ASX:FEX) | 21.1% | 45.1% |
| Acrux (ASX:ACR) | 15.6% | 106.9% |
| Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
| AVA Risk Group (ASX:AVA) | 16% | 108.2% |
| Titomic (ASX:TTT) | 11.2% | 77.2% |
| Plenti Group (ASX:PLT) | 12.7% | 120.1% |
| Change Financial (ASX:CCA) | 26.9% | 106.4% |
| BlueBet Holdings (ASX:BBT) | 39.2% | 77.5% |
| Findi (ASX:FND) | 35.6% | 120.7% |
Let's review some notable picks from our screened stocks.
Accent Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Accent Group Limited operates in the retail, distribution, and franchise sectors for lifestyle footwear, apparel, and accessories across Australia and New Zealand with a market cap of A$1.02 billion.
Operations: Accent Group's revenue is derived from its retail segment, which generated A$1.30 billion, and its wholesale segment, contributing A$475.92 million.
Insider Ownership: 14.8%
Accent Group, with significant insider ownership, has shown steady growth with recent half-year sales reaching A$775.96 million and net income of A$47.18 million. Despite a decrease in interim dividend to A$0.055 per share, the company trades at a substantial discount to its estimated fair value and is expected to grow earnings by 13.27% annually, outpacing the Australian market average. Recent board changes could enhance strategic direction and governance oversight.
Botanix Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★★
Overview: Botanix Pharmaceuticals Limited is involved in the research and development of dermatology and antimicrobial products across Australia and the United States, with a market cap of A$867.17 million.
Operations: The company generates revenue of A$2.07 million from its research and development activities in dermatology and antimicrobial products.
Insider Ownership: 10%
Botanix Pharmaceuticals, recently added to the S&P/ASX 300 and Small Ordinaries indices, exhibits potential for substantial growth despite a challenging financial backdrop. The company is forecasted to achieve significant revenue growth of over 100% annually and become profitable within three years. However, it faces hurdles with a recent net loss of A$30.89 million and insider selling activity. Trading significantly below its fair value estimate, Botanix remains an intriguing prospect in the Australian market.